Inactive Instrument

News Biostar Pharmaceuticals Inc Nasdaq

Equities

US0906782026

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2023	Biostar Pharmaceuticals, Inc. Announces FDA Approval of Utidelone Injectable Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer	CI
2023	Biostar Pharma, Inc. Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biostar Pharmaceuticals, Inc. Announces FDA Approval of Utidelone Injectable Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer	23-06-15	CI
Biostar Pharma, Inc. Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule	23-06-12	CI
Waiping Liu cancelled the acquisition of 16.2% stake in Biostar Pharmaceuticals, Inc. from Ronghua Wang.	19-06-01	CI
Biostar Pharmaceuticals, Inc.(NasdaqCM:BSPM) dropped from NASDAQ Composite Index	18-09-18	CI
Waiping Liu Discloses its Plans on Biostar Pharmaceuticals	18-07-02	CI
Waiping Liu entered into share purchase agreement to acquire 16.2% stake in Biostar Pharmaceuticals, Inc. from Ronghua Wang for $0.67 million.	18-07-01	CI
Biostar Pharmaceuticals, Inc. Announces Board Changes	18-02-02	CI
Biostar Pharmaceuticals, Inc. Appoints Melissa Fan Chen as an Independent Member of the Board and the Chair of the Audit Committee	17-12-28	CI
Biostar Pharmaceuticals, Inc. Announces Resignation of Leung King Fai as an Independent Director	17-12-18	CI
Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	17-11-20	CI
Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017	17-11-15	CI
Biostar Pharmaceuticals Seeks Acquisitions	17-11-15	CI
Biostar Pharmaceuticals, Inc. cancelled the acquisition of Xianyang Yongsheng Health Products Co., Ltd.	17-09-06	CI
Biostar Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017	17-05-19	CI
Biostar Pharmaceuticals, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2016	17-04-13	CI
Biostar Pharmaceuticals, Inc. Announces Management Changes	17-02-09	CI
Biostar Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016	16-11-21	CI
Biostar Pharmaceuticals, Inc. to Launch New Product Aimed at Treating Effects of Rhinitis and Sinusitis	16-10-11	CI
Biostar Pharmaceuticals, Inc. executed a non-binding letter of intent to acquire Xianyang Yongsheng Health Products Co., Ltd.	16-09-21	CI
Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016	16-08-22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Biostar Pharmaceuticals Inc Nasdaq

Equities

US0906782026

Summary

Filters